NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificNeutropenia
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020371
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
Phase 2
Completed
- Conditions
- Extraocular Extension MelanomaRecurrent Intraocular Melanoma
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020475
- Locations
- 🇺🇸
Surgery Branch, Bethesda, Maryland, United States
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Phase 1
Completed
- Conditions
- Epidemic Kaposi's SarcomaRecurrent Kaposi's Sarcoma
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019188
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Childhood Liver CancerBone CancerBrain TumorKidney TumorChildhood Soft Tissue Sarcoma
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019630
- Locations
- 🇺🇸
Pediatric Oncology Branch, Bethesda, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
Phase 2
Terminated
- Conditions
- Stage IV Prostate CancerBone MetastasesAdenocarcinoma of the ProstateRecurrent Prostate Cancer
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019695
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase 2
Completed
- Conditions
- Stage II Multiple MyelomaStage III Multiple MyelomaRefractory Plasma Cell Neoplasm
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019097
- Locations
- 🇺🇸
Arkansas Cancer Research Center, Little Rock, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Medicine Branch, Bethesda, Maryland, United States
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Stage IV Non-small Cell Lung CancerExtensive Stage Small Cell Lung CancerStage IIIA Non-small Cell Lung CancerRecurrent Small Cell Lung CancerStage IIIB Non-small Cell Lung CancerRecurrent Non-small Cell Lung Cancer
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020202
- Locations
- 🇺🇸
Surgery Branch, Bethesda, Maryland, United States
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Recurrent MelanomaStage IV Melanoma
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019448
- Locations
- 🇺🇸
Surgery Branch, Bethesda, Maryland, United States
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Phase 2
Completed
- Conditions
- Stage IV MelanomaRecurrent MelanomaRecurrent Renal Cell CancerStage IV Renal Cell Cancer
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019396
- Locations
- 🇺🇸
Surgery Branch, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Phase 2
Completed
- Conditions
- Stage III MelanomaRecurrent MelanomaStage IV Melanoma
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019890